Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
Go to source) medication directly to the brain through the nasal route. TB that affects the ... Nanoscale (Royal Society of Chemistry). The new treatment method also helps reduce the inflammation ...
GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand ... medication and many also fail to renew their ...
Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...
An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...
Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback